Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6655)
All Articles published online
|
Publishing Process of This Article
|
Jun 14, 2021 (publication date) through Apr 18, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Granito A, Muratori L, Lalanne C, Quarneti C, Ferri S, Guidi M, Lenzi M, Muratori P. Hepatocellular carcinoma in viral and autoimmune liver diseases: Role of CD4+ CD25+ Foxp3+ regulatory T cells in the immune microenvironment. World J Gastroenterol 2021; 27(22): 2994-3009 [PMID: 34168403 DOI: 10.3748/wjg.v27.i22.2994] |
|---|---|
| URL: | https://www.wjgnet.com/2644-3236/full/v27/i22/2994.htm |
| Number | Citing Articles |
| 1 |
Shu Zhao, Minhang Zhou, Peng Wang, Jing Yang, Dong Zhang, Fan Yin, Peng Song. Sorafenib, Lenvatinib, or Lenvatinib Combining PD-1 Inhibitors Plus TACE in Unresectable Hepatocellular Carcinoma: A Retrospective Analysis. Technology in Cancer Research & Treatment 2022; 21: 153303382211336 doi: 10.1177/15330338221133640
|
| 2 |
Tianming Chen, Changhao Zhu, Xing Wang, Yaozhen Pan, Alessandro Granito. LncRNA ELF3-AS1 is a Prognostic Biomarker and Correlated with Immune Infiltrates in Hepatocellular Carcinoma. Canadian Journal of Gastroenterology and Hepatology 2021; 2021: 1 doi: 10.1155/2021/8323487
|
| 3 |
Liyang Tang, Xiaoyong Lei, Haihong Hu, Zhuo Li, Hongxia Zhu, Wendi Zhan, Taolan Zhang. Investigation of fatty acid metabolism-related genes in breast cancer: Implications for Immunotherapy and clinical significance. Translational Oncology 2023; 34: 101700 doi: 10.1016/j.tranon.2023.101700
|
| 4 |
Huijing Dong, Chongxiang Xue, Yumin Zheng, Xu Zhang, Zixin Hu, Xingyu Lu, Yixuan Yu, Jia Li, Kexin Tan, Huijuan Cui, Alessandro Granito. Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Cancer and Hepatitis B or C: A Systematic Review and Meta-Analysis. Journal of Oncology 2023; 2023: 1 doi: 10.1155/2023/2525903
|
| 5 |
Menggang Zhang, Shuijun Zhang, Wenzhi Guo, Yuting He. Novel molecular hepatocellular carcinoma subtypes and RiskScore utilizing apoptosis-related genes. Scientific Reports 2024; 14(1) doi: 10.1038/s41598-024-54673-x
|
| 6 |
Yi Bai, Dapeng Chen, Chuanliang Cheng, Zhongmin Li, Hao Chi, Yuliang Zhang, Xiaoyu Zhang, Shaohai Tang, Qiang Zhao, Bing Ang, Yamin Zhang. Immunosuppressive landscape in hepatocellular carcinoma revealed by single-cell sequencing. Frontiers in Immunology 2022; 13 doi: 10.3389/fimmu.2022.950536
|
| 7 |
Hai-Chen Wang, Wen-Xuan Yin, Meng Jiang, Jia-Yi Han, Xing-Wang Kuai, Rui Sun, Yu-Feng Sun, Ju-Ling Ji. Function and biomedical implications of exosomal microRNAs delivered by parenchymal and nonparenchymal cells in hepatocellular carcinoma. World Journal of Gastroenterology 2023; 29(39): 5435-5451 doi: 10.3748/wjg.v29.i39.5435
Abstract(298) |
Core Tip(292) |
Full Article(HTML)(1642)
|
Full Article with Cover (PDF)-2155K(44)
|
Full Article (Word)-389K(24)
|
Audio-1515K(9)
|
Peer-Review Report-418K(27)
|
Answering Reviewers-791K(27)
|
Full Article (PDF)-1437K(126)
|
Full Article (XML)-356K(26)
|
Times Cited (2)
|
Total Visits (4104)
|
Open
|
| 8 |
Wanying Chen, Kexin Shu, Chenxi Cai, Jiatong Ding, Xin Zhang, Wenxiong Zhang, Kang Wang. Prognostic value and immune landscapes of immunogenic cell death-related lncRNAs in hepatocellular carcinoma. Bioscience Reports 2023; 43(9) doi: 10.1042/BSR20230634
|
| 9 |
Guiqin Xie, Ailin Zhu, Xinbin Gu. Converged DNA Damage Response Renders Human Hepatocellular Carcinoma Sensitive to CDK7 Inhibition. Cancers 2022; 14(7): 1714 doi: 10.3390/cancers14071714
|
| 10 |
Jiahao Liu, Baiying Liu, Yanan Li, Ze Mi, Hongpei Tan, Pengfei Rong. PCMT1 is a potential target related to tumor progression and immune infiltration in liver cancer. European Journal of Medical Research 2023; 28(1) doi: 10.1186/s40001-023-01216-1
|
| 11 |
Hiroyuki Abe, Kenya Kamimura, Shujiro Okuda, Yu Watanabe, Jun Inoue, Yutaka Aoyagi, Toshifumi Wakai, Ryo Kominami, Shuji Terai. BCL11B expression in hepatocellular carcinoma relates to chemosensitivity and clinical prognosis. Cancer Medicine 2023; 12(14): 15650 doi: 10.1002/cam4.6167
|
| 12 |
Tomoko Tadokoro, Takako Nomura, Koji Fujita, Takushi Manabe, Kei Takuma, Mai Nakahara, Kyoko Oura, Shima Mimura, Joji Tani, Asahiro Morishita, Hideki Kobara, Masafumi Ono, Tsutomu Masaki. Management of hepatocellular carcinoma, an important cause of death in Japanese autoimmune hepatitis patients. BMC Gastroenterology 2024; 24(1) doi: 10.1186/s12876-024-03204-z
|
| 13 |
Dizhi Jiang, Xinyue Ma, Xun Zhang, Bo Cheng, Ruiqing Wang, Yuan Liu, Xinyu Zhang. New techniques: a roadmap for the development of HCC immunotherapy. Frontiers in Immunology 2023; 14 doi: 10.3389/fimmu.2023.1121162
|
| 14 |
Ali Shojaeian, Mohsen Nakhaie, Zahra Sobhi Amjad, Armin Khaghani Boroujeni, Somayeh Shokri, Shahab Mahmoudvand. Leveraging metformin to combat hepatocellular carcinoma: its therapeutic promise against hepatitis viral infections. Journal of Cancer Metastasis and Treatment 2024; doi: 10.20517/2394-4722.2023.147
|
| 15 |
Nurbubu T. Moldogazieva, Sergey P. Zavadskiy, Susanna S. Sologova, Innokenty M. Mokhosoev, Alexander A. Terentiev. Predictive biomarkers for systemic therapy of hepatocellular carcinoma. Expert Review of Molecular Diagnostics 2021; 21(11): 1147 doi: 10.1080/14737159.2021.1987217
|
| 16 |
Nicolò Brandi, Matteo Renzulli. The Synergistic Effect of Interventional Locoregional Treatments and Immunotherapy for the Treatment of Hepatocellular Carcinoma. International Journal of Molecular Sciences 2023; 24(10): 8598 doi: 10.3390/ijms24108598
|
| 17 |
Jiang Guo, Wei Li, Long Cheng, Xuesong Gao. Identification and Validation of Hub Genes with Poor Prognosis in Hepatocellular Carcinoma by Integrated Bioinformatical Analysis. International Journal of General Medicine 2022; : 3933 doi: 10.2147/IJGM.S353708
|
| 18 |
Yan Li, Jing-Fei Zhao, Jie Zhang, Guo-Hua Zhan, Yuan-Kuan Li, Jun-Tao Huang, Xi Huang, Bang-De Xiang. Inflammation and Fibrosis in Patients with Non-Cirrhotic Hepatitis B Virus-Associated Hepatocellular Carcinoma: Impact on Prognosis after Hepatectomy and Mechanisms Involved. Current Oncology 2022; 30(1): 196 doi: 10.3390/curroncol30010016
|
| 19 |
Hao Zhang, Lin Sun, Xiao Hu, Alessandro Granito. Mast Cells Resting-Related Prognostic Signature in Hepatocellular Carcinoma. Journal of Oncology 2021; 2021: 1 doi: 10.1155/2021/4614257
|
| 20 |
Ji-Won Han, Seung-Kew Yoon. Immune Responses Following Locoregional Treatment for Hepatocellular Carcinoma: Possible Roles of Adjuvant Immunotherapy. Pharmaceutics 2021; 13(9): 1387 doi: 10.3390/pharmaceutics13091387
|
| 21 |
Nii Korley Kortei, Theophilus Annan, Vincent Kyei-Baffour, Edward Ken Essuman, Adjoa Agyemang Boakye, Clement Okraku Tettey, Nathaniel Owusu Boadi. Exposure assessment and cancer risk characterization of aflatoxin M1 (AFM1) through ingestion of raw cow milk in southern Ghana. Toxicology Reports 2022; 9: 1189 doi: 10.1016/j.toxrep.2022.05.015
|
| 22 |
Sha Qin, Gaoming Liu, Haoer Jin, Xue Chen, Jiang He, Juxiong Xiao, Yan Qin, Yitao Mao, Luqing Zhao. The comprehensive expression and functional analysis of m6A modification “readers” in hepatocellular carcinoma. Aging 2022; 14(15): 6269 doi: 10.18632/aging.204217
|
| 23 |
Xiaojing Chen, Hao Chi, Xiaozhao Zhao, Rui Pan, Ying Wei, Yunwei Han, Alessandro Granito. Role of Exosomes in Immune Microenvironment of Hepatocellular Carcinoma. Journal of Oncology 2022; 2022: 1 doi: 10.1155/2022/2521025
|
| 24 |
Maria Kotsari, Vassiliki Dimopoulou, John Koskinas, Athanasios Armakolas. Immune System and Hepatocellular Carcinoma (HCC): New Insights into HCC Progression. International Journal of Molecular Sciences 2023; 24(14): 11471 doi: 10.3390/ijms241411471
|
| 25 |
Kai Zhang, Enwu Yuan. Combined analysis of bulk and single-cell RNA sequencing reveals novel natural killer cell-related prognostic biomarkers for predicting immunotherapeutic response in hepatocellular carcinoma. Frontiers in Immunology 2023; 14 doi: 10.3389/fimmu.2023.1142126
|
| 26 |
Marta Maestri, Maria Pallozzi, Francesco Santopaolo, Lucia Cerrito, Maurizio Pompili, Antonio Gasbarrini, Francesca Romana Ponziani. Durvalumab: an investigational agent for unresectable hepatocellular carcinoma. Expert Opinion on Investigational Drugs 2022; 31(4): 347 doi: 10.1080/13543784.2022.2033208
|
| 27 |
Sugan Panneerselvam, Cornelia Wilson, Prem Kumar, Dinu Abirami, Jayakrishna Pamarthi, Mettu Srinivas Reddy, Joy Varghese. Overview of hepatocellular carcinoma: from molecular aspects to future therapeutic options. Cell Adhesion & Migration 2023; 17(1): 1 doi: 10.1080/19336918.2023.2258539
|
| 28 |
Toshimitsu Tanaka, Hironori Koga, Hiroyuki Suzuki, Hideki Iwamoto, Takahiko Sakaue, Atsutaka Masuda, Toru Nakamura, Jun Akiba, Hirohisa Yano, Takuji Torimura, Takumi Kawaguchi. Anti-PD-L1 antibodies promote cellular proliferation by activating the PD-L1–AXL signal relay in liver cancer cells. Hepatology International 2023; doi: 10.1007/s12072-023-10572-3
|
| 29 |
Weihao Chen, Xupeng Zhao, Yongliang Lu, Hanfeng Wang, Xiyou Wang, Yi Wang, Chen Liang, Zhuomin Jia, Wei Ma. Clinical significance, molecular characterization, and immune microenvironment analysis of coagulation‐related genes in clear cell renal cell carcinoma. Cancer Innovation 2024; 3(1) doi: 10.1002/cai2.105
|
| 30 |
Zhong Maoxi, Xue Jinmin, Zeng Xiaozhu, Yue Yubing, Zhu Yuxi, Alessandro Granito. PD-1/PD-L1 Inhibitors versus Chemotherapy for Previously Treated Advanced Gastroesophageal Cancer: A Meta-Analysis of Randomized Controlled Trials. Journal of Oncology 2021; 2021: 1 doi: 10.1155/2021/3048974
|
| 31 |
Juan Manuel Velázquez-Enríquez, Renata Cerna, Olga Beltrán-Ramírez, Carolina Piña-Vázquez, Saúl Villa-Treviño, Verónica Rocío Vásquez-Garzón. DCLK1 is Overexpressed and Associated with Immune Cell Infiltration in Hepatocellular Carcinoma. Biochemical Genetics 2024; doi: 10.1007/s10528-024-10667-y
|
| 32 |
Qifan He, Jian Yang, Yonghai Jin. Immune infiltration and clinical significance analyses of the coagulation-related genes in hepatocellular carcinoma. Briefings in Bioinformatics 2022; 23(4) doi: 10.1093/bib/bbac291
|
| 33 |
Shanshan Chen, Hualei Chen, Yongchao Zhang, Wei Li. Efficacy and Safety of Cellular Immunotherapy by Local Infusion for Liver Tumor: A Systematic Review and Meta-Analysis. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.772509
|
| 34 |
Subhadra Kumari, Santosh Kumar, Srinivasan Muthuswamy. RNA N6-methyladenosine modification in regulating cancer stem cells and tumor immune microenvironment and its implication for cancer therapy. Journal of Cancer Research and Clinical Oncology 2023; 149(4): 1621 doi: 10.1007/s00432-022-04158-z
|
| 35 |
Yiyang Tang, Yanqin Wu, Miao Xue, Bowen Zhu, Wenzhe Fan, Jiaping Li, Alessandro Granito. A 10-Gene Signature Identified by Machine Learning for Predicting the Response to Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma. Journal of Oncology 2022; 2022: 1 doi: 10.1155/2022/3822773
|
| 36 |
Song-Huy Nguyen-Dinh, Wei-Feng Li, Yueh-Wei Liu, Chih-Chi Wang, Yen-Hao Chen, Jing-Houng Wang, Chao-Hung Hung. Comparisons of Viral Etiology and Outcomes of Hepatocellular Carcinoma Undergoing Liver Resection between Taiwan and Vietnam. Viruses 2022; 14(11): 2571 doi: 10.3390/v14112571
|
| 37 |
Xudong Ren, Yanqin Ju, Chaoqun Wang, Ran Wei, Haoting Sun, Quanbao Zhang. MARCKS on Tumor-Associated Macrophages is Correlated with Immune Infiltrates and Poor Prognosis in Hepatocellular Carcinoma. Cancer Investigation 2021; 39(9): 756 doi: 10.1080/07357907.2021.1950757
|
| 38 |
Yan Lu, Bo Lin, Mengsen Li. The role of alpha-fetoprotein in the tumor microenvironment of hepatocellular carcinoma. Frontiers in Oncology 2024; 14 doi: 10.3389/fonc.2024.1363695
|
| 39 |
Meng-Ting Li, Kai-Feng Zheng, Yi-Er Qiu. Identification of immune cell-related prognostic genes characterized by a distinct microenvironment in hepatocellular carcinoma. World Journal of Clinical Oncology 2024; 15(2): 243-270 doi: 10.5306/wjco.v15.i2.243
Abstract(89) |
Core Tip(98) |
Full Article(HTML)(600)
|
Full Article with Cover (PDF)-20601K(13)
|
Full Article (Word)-1213K(8)
|
Audio-835K(1)
|
Peer-Review Report-213K(10)
|
Answering Reviewers-57K(8)
|
Full Article (PDF)-20368K(26)
|
Full Article (XML)-144K(14)
|
Times Cited (0)
|
Total Visits (1495)
|
Open
|
| 40 |
Chou-Yi Hsu, Mohammed Ahmed Mustafa, Ashwani Kumar, Atreyi Pramanik, Rajiv Sharma, Faraj Mohammed, Israa Abed Jawad, Imad Jasim Mohammed, Mohammad Y. Alshahrani, Noor Alhuda Mohammad Ali khalil, Ali Turki Shnishil, Munther Kadhim Abosaoda. Exploiting the immune system in hepatic tumor targeting: Unleashing the potential of drugs, natural products, and nanoparticles. Pathology - Research and Practice 2024; 256: 155266 doi: 10.1016/j.prp.2024.155266
|
| 41 |
Michelle Harriz Braga, Guilherme Grossi Lopes Cançado, Paulo Lisboa Bittencourt, Cláudia Alves Couto, Laura Vilar Guedes, André Mourão Costa Lima, Maria Lucia Gomes Ferraz, Cristiane Alves Villela-Nogueira, Mateus Jorge Nardelli, Luciana Costa Faria, Nathalia Mota de Faria Gomes, Elze Maria Gomes Oliveira, Vivian Rotman, Maria Beatriz Oliveira, Simone Muniz Carvalho Fernandes da Cunha, Marlone Cunha-Silva, Liliana Sampaio Costa Mendes, Claudia Alexandra Pontes Ivantes, Liana Codes, Valéria Ferreira de Almeida e Borges, Fabio Heleno de Lima Pace, Mario Guimarães Pessoa, Izabelle Venturini Signorelli, Gabriela Perdomo Coral, João Galizzi Filho, Aline Lopes Chagas, Debora Raquel Benedita Terrabuio, Eduardo Luiz Rachid Cançado. Risk factors for cancer in patients with primary biliary cholangitis and autoimmune hepatitis and primary biliary cholangitis overlap syndrome. Annals of Hepatology 2023; 28(4): 101105 doi: 10.1016/j.aohep.2023.101105
|
| 42 |
Luwen Xing, Yiwen Zhang, Saiyu Li, Minghui Tong, Kaishun Bi, Qian Zhang, Qing Li. A Dual Coverage Monitoring of the Bile Acids Profile in the Liver–Gut Axis throughout the Whole Inflammation-Cancer Transformation Progressive: Reveal Hepatocellular Carcinoma Pathogenesis. International Journal of Molecular Sciences 2023; 24(5): 4258 doi: 10.3390/ijms24054258
|
| 43 |
Young Eun Chon, Sung Jun Park, Man Young Park, Yeonjung Ha, Joo Ho Lee, Kwan Sik Lee, Eileen L. Yoon, Dae Won Jun. Extrahepatic Malignancies Are the Leading Cause of Death in Patients with Chronic Hepatitis B without Cirrhosis: A Large Population-Based Cohort Study. Cancers 2024; 16(4): 711 doi: 10.3390/cancers16040711
|
| 44 |
Hongyang Deng, Tengfei Li, Fengxian Wei, Wei Han, Xiaodong Xu, Youcheng Zhang. High expression of TMEM200A is associated with a poor prognosis and immune infiltration in gastric cancer. Pathology and Oncology Research 2023; 29 doi: 10.3389/pore.2023.1610893
|
| 45 |
Bao-Jiang Liu, Song Gao, Xu Zhu, Jian-Hai Guo, Fu-Xin Kou, Shao-Xing Liu, Xin Zhang, Xiao-Dong Wang, Guang Cao, Hui Chen, Peng Liu, Hai-Feng Xu, Qin-Zong Gao, Ren-Jie Yang. Real-world study of hepatic artery infusion chemotherapy combined with anti-PD-1 immunotherapy and tyrosine kinase inhibitors for advanced hepatocellular carcinoma. Immunotherapy 2021; 13(17): 1395 doi: 10.2217/imt-2021-0192
|
| 46 |
Yang Liu, Xia Xiao, Jingying Wang, Yitong Wang, Yanhui Yu. Silencing CircEIF3I/miR-526b-5p Axis Epigenetically Targets HGF/c-Met Signal to Hinder the Malignant Growth, Metastasis and Angiogenesis of Hepatocellular Carcinoma. Biochemical Genetics 2023; 61(1): 48 doi: 10.1007/s10528-022-10239-y
|
| 47 |
Fahui Liu, Jiadong Liang, Puze Long, Lilan Zhu, Wanyun Hou, Xueming Wu, Chunying Luo. ZCCHC17 Served as a Predictive Biomarker for Prognosis and Immunotherapy in Hepatocellular Carcinoma. Frontiers in Oncology 2022; 11 doi: 10.3389/fonc.2021.799566
|
| 48 |
Lijun Xu, Qing Zheng, Alessandro Granito. A Novel Expression Signature from the Perspective of Mesenchymal-Epithelial Transition for Hepatocellular Carcinoma with Regard to Prognosis, Clinicopathological Features, Immune Cell Infiltration, Chemotherapeutic Efficacy, and Immunosuppressive Molecules. Journal of Oncology 2021; 2021: 1 doi: 10.1155/2021/5033416
|
| 49 |
Feihua Chen, Mouchun Gong, Dengcheng Weng, Zhaoqing Jin, Guofeng Han, Ziqiang Yang, Junjun Han, Jianjiang Wang. Phellinus linteus activates Treg cells via FAK to promote M2 macrophage polarization in hepatocellular carcinoma. Cancer Immunology, Immunotherapy 2024; 73(1) doi: 10.1007/s00262-023-03592-3
|
| 50 |
Hui Nie, Yutong Wang, Xuejie Yang, Zhiming Liao, Xiaoyun He, Jianhua Zhou, Chunlin Ou. Clinical Significance and Integrative Analysis of the SMC Family in Hepatocellular Carcinoma. Frontiers in Medicine 2021; 8 doi: 10.3389/fmed.2021.727965
|
| 51 |
Weili Liu, Yuan Gao, Hua Li, Xinxing Wang, Min Jin, Zhiqiang Shen, Dong Yang, Xuelian Zhang, Zilin Wei, Zhaoli Chen, Junwen Li. Association between oxidative stress, mitochondrial function of peripheral blood mononuclear cells and gastrointestinal cancers. Journal of Translational Medicine 2023; 21(1) doi: 10.1186/s12967-023-03952-8
|
| 52 |
Eun Ju Cho, Su Jong Yu, Yun Bin Lee, Jeong-Hoon Lee, Yoon Jun Kim, Jung-Hwan Yoon. Prognostic Values of Inflammation-Based Scores and Fibrosis Markers in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization. Diagnostics 2022; 12(5): 1170 doi: 10.3390/diagnostics12051170
|
| 53 |
Junjie Liu, Haisu Tao, Tong Yuan, Jiang Li, Jian Li, Huifang Liang, Zhiyong Huang, Erlei Zhang. Immunomodulatory effects of regorafenib: Enhancing the efficacy of anti-PD-1/PD-L1 therapy. Frontiers in Immunology 2022; 13 doi: 10.3389/fimmu.2022.992611
|
| 54 |
Dawei Cui, Daixi Jiang, Cuilin Yan, Xia Liu, Yan Lv, Jue Xie, Yu Chen. Immune Checkpoint Molecules Expressed on CD4+ T Cell Subsets in Chronic Asymptomatic Hepatitis B Virus Carriers With Hepatitis B e Antigen-Negative. Frontiers in Microbiology 2022; 13 doi: 10.3389/fmicb.2022.887408
|
| 55 |
Nicholas Noverati, Rukaiya Bashir-Hamidu, Dina Halegoua-DeMarzio, Hie-Won Hann. Hepatitis B Virus-Associated Hepatocellular Carcinoma and Chronic Stress. International Journal of Molecular Sciences 2022; 23(7): 3917 doi: 10.3390/ijms23073917
|
| 56 |
Xueyan Wei, Zihan Zhou, Meiying Long, Qiuling Lin, Moqin Qiu, Peiqin Chen, Qiongguang Huang, Jialin Qiu, Yanji Jiang, Qiuping Wen, Yingchun Liu, Runwei Li, Cunli Nong, Qian Guo, Hongping Yu, Xianguo Zhou. A novel signature constructed by super-enhancer-related genes for the prediction of prognosis in hepatocellular carcinoma and associated with immune infiltration. Frontiers in Oncology 2023; 13 doi: 10.3389/fonc.2023.1043203
|
| 57 |
Bingtian Dong, Yuping Chen, Guorong Lyu, Xiaocen Yang. Aspartate Aminotransferase to Platelet Ratio Index and Fibrosis-4 Index for Detecting Liver Fibrosis in Patients With Autoimmune Hepatitis: A Meta-Analysis. Frontiers in Immunology 2022; 13 doi: 10.3389/fimmu.2022.892454
|
| 58 |
Ming-Ling Chang, Wei-Ting Chen, Tien-Ming Chan, Cheng-Yu Lin, Ming-Yu Chang, Shiang-Chi Chen, Rong-Nan Chien. Anti-Mitochondrial Antibody Titers Decrease Over Time in Primary Biliary Cholangitis Patients With Ursodeoxycholic Acid Therapeutic Response: A Cohort Study Followed Up to 28 Years. Frontiers in Immunology 2022; 13 doi: 10.3389/fimmu.2022.869018
|
| 59 |
Jiajing Zhao, Zeminshan Luo, Ruizhi Fu, Jinghong Zhou, Shubiao Chen, Jianjie Wang, Dewang Chen, Xiaojun Xie. Disulfidptosis-related signatures for prognostic and immunotherapy reactivity evaluation in hepatocellular carcinoma. European Journal of Medical Research 2023; 28(1) doi: 10.1186/s40001-023-01535-3
|
| 60 |
Iñigo Les, Mireia Martínez, Inés Pérez-Francisco, María Cabero, Lucía Teijeira, Virginia Arrazubi, Nuria Torrego, Ana Campillo-Calatayud, Iñaki Elejalde, Grazyna Kochan, David Escors. Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events. Cancers 2023; 15(5): 1629 doi: 10.3390/cancers15051629
|
| 61 |
Rui Zou, Yunhe Hao, Yiyao Wang, Feihu Yan, Xu Peng, Zepeng Huang, Gang Chen. A multicenter retrospective analysis: Factors influencing hepatic adverse events induced by immunotherapy in advanced liver cancer. Cancer Reports 2024; 7(2) doi: 10.1002/cnr2.1918
|
| 62 |
Annabelle Vogt, Farsaneh Sadeghlar, Tiyasha H. Ayub, Carlo Schneider, Christian Möhring, Taotao Zhou, Robert Mahn, Alexandra Bartels, Michael Praktiknjo, Miroslaw T. Kornek, Marieta Toma, Ingo G. H. Schmidt-Wolf, Vittorio Branchi, Hanno Matthaei, Jörg C. Kalff, Christian P. Strassburg, Maria A. Gonzalez-Carmona. Alpha-Fetoprotein- and CD40Ligand-Expressing Dendritic Cells for Immunotherapy of Hepatocellular Carcinoma. Cancers 2021; 13(13): 3375 doi: 10.3390/cancers13133375
|
| 63 |
Qifan He, Jian Yang, Yonghai Jin. Development and Validation of TACE Refractoriness-Related Diagnostic and Prognostic Scores and Characterization of Tumor Microenvironment Infiltration in Hepatocellular Carcinoma. Frontiers in Immunology 2022; 13 doi: 10.3389/fimmu.2022.869993
|
| 64 |
Yi Feng, Chengyang Li, Yuan Ji, Ying Liu, Lu Gan, Yiyi Yu, Tianshu Liu. Nivolumab Combined With Ipilimumab Treatment Induced Hypophysitis and Immune-Mediated Liver Injury in Advanced Esophageal Squamous Cell Carcinoma: A Case Report. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.801924
|
| 65 |
Gong Zhang, Junhui Hou, Chenxue Mei, Xia Wang, Yuan Wang, Kefeng Wang. Effect of circular RNAs and N6-methyladenosine (m6A) modification on cancer biology. Biomedicine & Pharmacotherapy 2023; 159: 114260 doi: 10.1016/j.biopha.2023.114260
|
| 66 |
Hui Yang, Chenfei Zhou, Fei Yuan, Liting Guo, Liu Yang, Yan Shi, Jun Zhang. Case Report: Severe Immune-Related Cholestatic Hepatitis and Subsequent Pneumonia After Pembrolizumab Therapy in a Geriatic Patient With Metastic Gastric Cancer. Frontiers in Medicine 2021; 8 doi: 10.3389/fmed.2021.719236
|
| 67 |
Hao Zhang, Renzheng Liu, Lin Sun, Weidong Guo, Xiao Hu, Alessandro Granito. The Effect of Ferroptosis-Related Genes on Prognosis and Tumor Mutational Burden in Hepatocellular Carcinoma. Journal of Oncology 2021; 2021: 1 doi: 10.1155/2021/7391560
|
| 68 |
M. A. Dudina, S. A. Dogadin, A. A. Savchenko, V. D. Belenyuk. T-lymphocytes phenotypic composition of peripheral blood in patients with Graves’ disease undergoing conservative therapy with thiamazole. Problems of Endocrinology 2021; 67(6): 39 doi: 10.14341/probl12812
|
| 69 |
Rongqiang Liu, Rongqi Li, Haoyuan Yu, Jianrong Liu, Shiyang Zheng, Yang Li, Linsen Ye. NTF3 Correlates With Prognosis and Immune Infiltration in Hepatocellular Carcinoma. Frontiers in Medicine 2021; 8 doi: 10.3389/fmed.2021.795849
|
| 70 |
Jung Wan Choe, Hye Yoon Lee, Chai Hong Rim. Will the collaboration of surgery and external radiotherapy open new avenues for hepatocellular carcinoma with portal vein thrombosis?. World Journal of Gastroenterology 2022; 28(7): 704-714 doi: 10.3748/wjg.v28.i7.704
|
| 71 |
Bernardo Stefanini, Luca Ielasi, Rusi Chen, Chiara Abbati, Matteo Tonnini, Francesco Tovoli, Alessandro Granito. TKIs in combination with immunotherapy for hepatocellular carcinoma. Expert Review of Anticancer Therapy 2023; 23(3): 279 doi: 10.1080/14737140.2023.2181162
|
| 72 |
Rui-Qian Gao, Jing-Han Sun, Yong-Hui Ma, Yu-Wei Xie, Guan-Ming Shao, Cong Wang, Bin Tan, Kui Liu, Kun Li, Na Li, Wei-Yu Hu, Jingyu Cao, Alessandro Granito. Circulating the HLA-DR+ T Cell Ratio Is a Prognostic Factor for Recurrence of Patients with Hepatocellular Carcinoma after Curative Surgery. Journal of Oncology 2023; 2023: 1 doi: 10.1155/2023/1875153
|
| 73 |
Yu-Xin Guo, Na Wang, Wen-Cheng Wu, Cui-Qin Li, Rui-Heng Chen, Yuan Zhang, Xing Li, Alessandro Granito. The Role of miR-23b in Cancer and Autoimmune Disease. Journal of Oncology 2021; 2021: 1 doi: 10.1155/2021/6473038
|
| 74 |
Guilherme Grossi Lopes Cançado, Michelle Harriz Braga, Maria Lúcia Gomes Ferraz, Cristiane Alves Villela-Nogueira, Debora Raquel Benedita Terrabuio, Eduardo Luiz Rachid Cançado, Mateus Jorge Nardelli, Luciana Costa Faria, Nathalia Mota de Faria Gomes, Elze Maria Gomes de Oliveira, Vivian Rotman, Maria Beatriz de Oliveira, Simone Muniz Carvalho Fernandes da Cunha, Daniel Ferraz de Campos Mazo, Liliana Sampaio Costa Mendes, Claudia Alexandra Pontes Ivantes, Liana Codes, Valéria Ferreira de Almeida e Borges, Fabio Heleno de Lima Pace, Mario Guimarães Pessoa, Izabelle Venturini Signorelli, Gabriela Perdomo Coral, Paulo Lisboa Bittencourt, Cynthia Levy, Cláudia Alves Couto. Clinical features and treatment outcomes of primary biliary cholangitis in a highly admixed population. Annals of Hepatology 2022; 27(1): 100546 doi: 10.1016/j.aohep.2021.100546
|
| 75 |
Mehmet Akce, Bassel F. El-Rayes, Tanios S. Bekaii-Saab. Frontline therapy for advanced hepatocellular carcinoma: an update. Therapeutic Advances in Gastroenterology 2022; 15: 175628482210861 doi: 10.1177/17562848221086126
|
| 76 |
Qingmiao Shi, Yifan Zeng, Chen Xue, Qingfei Chu, Xin Yuan, Lanjuan Li. Development of a promising PPAR signaling pathway-related prognostic prediction model for hepatocellular carcinoma. Scientific Reports 2024; 14(1) doi: 10.1038/s41598-024-55086-6
|
| 77 |
Jin Lei, Bowen Chen, Meiru Song, Linzhi Zhang, Xinfeng Zhang, Xiaoqiang Gao, Yinyin Li, Yinying Lu, Shi Zuo. TKI or TKI combined with PD-1 inhibitors as second-line treatment for HCC patients after sorafenib failure. Frontiers in Pharmacology 2022; 13 doi: 10.3389/fphar.2022.1026337
|
| 78 |
Atezolizumab plus bevacizumab as a downstaging therapy for liver transplantation in hepatocellular carcinoma with portal vein thrombosis: The first report. American Journal of Transplantation 2024; doi: 10.1016/j.ajt.2024.01.007
|
| 79 |
Yongkang Xu, Shumin Fu, Kai Shang, Jiayu Zeng, Ye Mao. PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus regorafenib in patients with advanced hepatocellular carcinoma after failure of sorafenib. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.958869
|
| 80 |
Dongqing Gu, Min Zhang, Yutong Wang, Ye Bai, Xin Wang, Guohong Deng. Causal effect of autoimmune liver diseases on cancer: Meta‐analyses of cohort studies and Mendelian randomization study. Liver International 2022; 42(10): 2216 doi: 10.1111/liv.15355
|
| 81 |
Kehua Jiang, Tao Ye, Juan Du, Lanlan Tang, Xiaolong Chen, Fa Sun, Xifeng Sun, Alessandro Granito. Elevated P-Element-Induced Wimpy-Testis-Like Protein 1 Expression Predicts Unfavorable Prognosis for Patients with Various Cancers. Journal of Oncology 2021; 2021: 1 doi: 10.1155/2021/9982192
|
| 82 |
Rongqi Li, Rongqiang Liu, Shiyang Zheng, Wenbin Liu, Hui Li, Dewei Li, Alessandro Granito. Comprehensive Analysis of Prognostic Value and Immune Infiltration of the NT5DC Family in Hepatocellular Carcinoma. Journal of Oncology 2022; 2022: 1 doi: 10.1155/2022/2607878
|
| 83 |
Yingying Bao, Liang Wen, Wen Chen, Jianhui Zhao, Yixiao Yang, Tao Wei, Jian Zhang, Tingbo Liang. Case report: A case of heterogeneity of the antitumor response to immune checkpoint inhibitors in a patient with relapsed hepatocellular carcinoma. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.899811
|
| 84 |
Sabrina Ceeraz, Charlotte R. Thompson, Richard Beatson, Ernest H. Choy. Harnessing CD8+CD28− Regulatory T Cells as a Tool to Treat Autoimmune Disease. Cells 2021; 10(11): 2973 doi: 10.3390/cells10112973
|
| 85 |
Nan Zhang, Yuxin Zuo, Yu Peng, Lielian Zuo, Alessandro Granito. Function of N6-Methyladenosine Modification in Tumors. Journal of Oncology 2021; 2021: 1 doi: 10.1155/2021/6461552
|
| 86 |
Daniel Ronen, Aseel Bsoul, Michal Lotem, Suzan Abedat, Merav Yarkoni, Offer Amir, Rabea Asleh. Exploring the Mechanisms Underlying the Cardiotoxic Effects of Immune Checkpoint Inhibitor Therapies. Vaccines 2022; 10(4): 540 doi: 10.3390/vaccines10040540
|
| 87 |
Hao Zhang, Lin Sun, Xiao Hu, Alessandro Granito. Macrophages M1-Related Prognostic Signature in Hepatocellular Carcinoma. Journal of Oncology 2021; 2021: 1 doi: 10.1155/2021/6347592
|
| 88 |
Nii Korley Kortei, Valentina Sylvia Gillette, Michael Wiafe-Kwagyan, Leslie Owusu Ansah, Vincent Kyei-Baffour, George Tawia Odamtten. Fungal profile, levels of aflatoxin M1, exposure, and the risk characterization of local cheese ‘wagashi’ consumed in the Ho Municipality, Volta Region, Ghana. Toxicology Reports 2024; 12: 186 doi: 10.1016/j.toxrep.2024.01.009
|
| 89 |
Lien-Hung Huang, Cheng-Shyuan Rau, Yueh-Wei Liu, Chia-Jung Wu, Peng-Chen Chien, Hui-Ping Lin, Yi-Chan Wu, Chun-Ying Huang, Ting-Min Hsieh, Ching-Hua Hsieh. Exploring the Regulatory Role of XIST-microRNAs/mRNA Network in Circulating CD4+ T Cells of Hepatocellular Carcinoma Patients. Biomedicines 2023; 11(7): 1848 doi: 10.3390/biomedicines11071848
|
| 90 |
Ran Wei, Ou Qi Feng, Yao Ze Hui, Xiaohui Huang, Li Sheng Ping. Prognostic value of the S100 calcium-binding protein family members in hepatocellular carcinoma. Bioscience Reports 2023; 43(7) doi: 10.1042/BSR20222523
|
| 91 |
Le Xiong, Fang-Chen Liu. Immune function status of postoperative patients with colon cancer for predicting liver metastasis. World Journal of Gastrointestinal Surgery 2024; 16(2): 463-470 doi: 10.4240/wjgs.v16.i2.463
Abstract(79) |
Core Tip(67) |
Full Article(HTML)(329)
|
Full Article with Cover (PDF)-795K(24)
|
Full Article (Word)-243K(5)
|
Audio-1724K(0)
|
Peer-Review Report-240K(9)
|
Answering Reviewers-244K(8)
|
Full Article (PDF)-538K(29)
|
Full Article (XML)-79K(9)
|
Times Cited (0)
|
Total Visits (983)
|
Open
|
| 92 |
Feicui Li, Haijun Tang, Xiaoting Luo, Xiangde Li, Kai Luo, Shangyu Liu, Jiming Liang, Shijie Liao, Chaoyi Zhong, Xinli Zhan, Qingjun Wei, Wenyu Feng, Yun Liu. Interaction gene set between osteoclasts and regulatory CD4+ T cells can accurately predict the prognosis of patients with osteosarcoma. Cancer Science 2023; 114(7): 3014 doi: 10.1111/cas.15821
|
| 93 |
Jianlin Chen, Gan Gao, Yufang He, Yi Zhang, Haixia Wu, Peng Dai, Qingzhu Zheng, Hengbin Huang, Jiamiao Weng, Yue Zheng, Yi Huang. Construction and validation of a novel lysosomal signature for hepatocellular carcinoma prognosis, diagnosis, and therapeutic decision-making. Scientific Reports 2023; 13(1) doi: 10.1038/s41598-023-49985-3
|
| 94 |
Quang Minh Dang, Ryu Watanabe, Mayu Shiomi, Kazuo Fukumoto, Tomomi W. Nobashi, Tadashi Okano, Shinsuke Yamada, Motomu Hashimoto. Rheumatic Immune-Related Adverse Events due to Immune Checkpoint Inhibitors—A 2023 Update. International Journal of Molecular Sciences 2023; 24(6): 5643 doi: 10.3390/ijms24065643
|
| 95 |
Zhi-Yong Liu, Dan-Ying Zhang, Xia-Hui Lin, Jia-Lei Sun, Weinire Abuduwaili, Guang-Cong Zhang, Ru-Chen Xu, Fu Wang, Xiang-Nan Yu, Xuan Shi, Bin Deng, Ling Dong, Shu-Qiang Weng, Ji-Min Zhu, Xi-Zhong Shen, Tao-Tao Liu. Nalidixic acid potentiates the antitumor activity in sorafenib-resistant hepatocellular carcinoma via the tumor immune microenvironment analysis. Frontiers in Pharmacology 2022; 13 doi: 10.3389/fphar.2022.952482
|
| 96 |
Hao Xie, Diego M Alem Glison, Richard D. Kim. FGFR4 inhibitors for the treatment of hepatocellular carcinoma: a synopsis of therapeutic potential. Expert Opinion on Investigational Drugs 2022; 31(4): 393 doi: 10.1080/13543784.2022.2017879
|
| 97 |
Iman H. Ibrahim, Ola Sayed M. Ali, Adel A. El-Sahar, Mohamed Elrefaei, Nabila El-Sheikh. Telomerase Expression Related with Poor Immune Response to HCV Core Antigen in Egyptian HCV Patients’ PBMCs. Journal of Clinical and Experimental Hepatology 2023; 13(6): 1008 doi: 10.1016/j.jceh.2023.06.004
|
| 98 |
Qingqing Li, Tong Su, Xu Zhang, Yanfeng Pan, Shengli Ma, Lu Zhang, Xianqiang Zhang, Xiaojuan Gao. A Real-World Study of Optimal Treatment with Anlotinib First-Line Therapy in Advanced Hepatocellular Carcinoma. Cancer Management and Research 2022; : 3037 doi: 10.2147/CMAR.S379911
|
| 99 |
Nevin Varghese, Amry Majeed, Suraj Nyalakonda, Tina Boortalary, Dina Halegoua-DeMarzio, Hie-Won Hann. Review of Related Factors for Persistent Risk of Hepatitis B Virus-Associated Hepatocellular Carcinoma. Cancers 2024; 16(4): 777 doi: 10.3390/cancers16040777
|
| 100 |
Mona A. Omar, Mohamed M. Omran, Khaled Farid, Ashraf A. Tabll, Yasser E. Shahein, Tarek M. Emran, Ana Petrovic, Nikola R. Lucic, Robert Smolic, Tanja Kovac, Martina Smolic. Biomarkers for Hepatocellular Carcinoma: From Origin to Clinical Diagnosis. Biomedicines 2023; 11(7): 1852 doi: 10.3390/biomedicines11071852
|